0.94
1.05%
-0.01
Estrella Immunopharma Inc stock is currently priced at $0.94, with a 24-hour trading volume of 5,850.
It has seen a -1.05% decreased in the last 24 hours and a -10.05% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9474 pivot point. If it approaches the $0.9048 support level, significant changes may occur.
Previous Close:
$0.95
Open:
$0.94
24h Volume:
5,850
Market Cap:
$34.19M
Revenue:
-
Net Income/Loss:
$-8.53M
P/E Ratio:
-8.0617
EPS:
-0.1166
Net Cash Flow:
$-12.75M
1W Performance:
+4.56%
1M Performance:
-10.05%
6M Performance:
-24.80%
1Y Performance:
+0.00%
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
510 318 9098
Address
5858 Horton Street, Suite 170, EmeryVille
Estrella Immunopharma Inc Stock (ESLA) Latest News
We Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business Growth - Yahoo Movies UK
Yahoo Movies UK
Ratio Analysis: Unpacking Estrella Immunopharma Inc (ESLA)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 - InvestorPlace
InvestorPlace
Morning SPAC News Roundup: January 31, 2024|SPACInsider - SPACInsider
SPACInsider
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace
InvestorPlace
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Benzinga
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Estrella Immunopharma Inc (ESLA) Net Income 2024
ESLA net income (TTM) was -$8.53 million for the quarter ending December 31, 2023.
Estrella Immunopharma Inc (ESLA) Cash Flow 2024
ESLA recorded a free cash flow (TTM) of -$12.75 million for the quarter ending December 31, 2023.
Estrella Immunopharma Inc (ESLA) Earnings per Share 2024
ESLA earnings per share (TTM) was -$0.2434 for the quarter ending December 31, 2023.
About Estrella Immunopharma Inc
Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company, develops cancer therapeutics. It develops CD19 and CD20-targeted T-cell therapies for the treatment of blood cancers and solid tumors. Estrella Biopharma, Inc. was incorporated in 2022 and is based in Emeryville, California.
Cap:
|
Volume (24h):